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Abstract. The Hedgehog-Gli (Hh-Gli) signaling pathway was 
examined in ovarian dermoids, which show characteristics 
of both tumors and developmental malformations. Dermoids 
are classified as mature teratomas that present differentia-
tion into various tissues, mostly epidermal elements such as 
glands, multilayered epithelium, hair follicles and occasionally 
bone and cartilage. Their development is attributed to aber-
rant meiosis of germinal cells within the ovary. We showed 
activation of the Hh-Gli signaling in ovarian dermoid primary 
cultures. Cyclopamine treatment slows down cell prolifera-
tion, while the Sonic Hedgehog (Shh) protein stimulates cell 
proliferation and induces internalization of the Patched (Ptch) 
protein, which accumulates in the form of granules in the 
cytoplasm, colocalized with the Shh protein. Cyclopamine 
treatment decreases Gli1 localization in the nucleus compared 
to non-treated cells. Based on our observations, the mecha-
nism of Hedgehog activation in the ovarian dermoids could 
be the ligand-dependent autocrine pathway, which can also be 
stimulated by paracrine signals.
Introduction
The Hh-Gli signaling pathway plays a crucial role in embryo-
genesis, but it is mostly inactive in adult tissues under normal 
conditions. The signaling transduction is initialized by the 
ligand Hedgehog with three different isoforms in humans: 
the Sonic Hedgehog (Shh), the Indian Hedgehog (Ihh) and the 
Desert Hedgehog (Dhh), which bind to the transmembrane 
receptor Patched (Ptch), inducing their internalization and 
translocation of Smoothened (Smo) to the membrane. A cyto-
plasmatic cascade of phosphorylation events leads to activation 
of the transcription factor Gli, which translocates to the nucleus 
and initializes target gene transcription (1). The pathway 
activity is associated with the formation of various tissues and 
organs: neural tube, limbs, gastrointestinal system, lung, hair 
follicles, cartilage and bone (2), pancreas (3) and ganglia (4). 
In the adult organism it is associated with somatic stem cells, 
for example, breast (5), neural (6), lung (7), skin (8) and eryth-
ropoietic cells (9). When deregulated, it can lead to various 
tumors, for example, basocellular carcinoma, melanoma, 
trychoepithelioma, rhabdomyosarcoma, digestive tract tumors, 
prostate tumors, small-cell lung cancer, squamous lung cancer, 
pancreatic cancer, breast cancer and ovarian cancer (10). 
The role of Hh-Gli signaling in ovarian development and 
malignancy has been explored by several groups. It has been 
shown that the pathway is involved in embryonic development 
and maturation of Drosophila ovaries, while in the adult fly it 
is involved in the division of stem cells giving rise to follicles 
(11). In mammals, the Hh-Gli pathway is also involved in 
embryonic development of the ovary, and in the adult organism 
components of the pathway are expressed in reproductive 
tissues (12). In the adult ovary, the Hh-Gli signaling is active 
in the granulose cells surrounding the follicle, and it can be 
additionally activated by exogenous Shh protein (13).
Ovarian carcinomas express Hh-Gli pathway genes, and 
in ovarian cancer cell lines cyclopamine, a known Hh-Gli 
pathway inhibitor, causes G1 cell cycle arrest (14). Also, 
ovarian carcinomas frequently show loss of one allele of the 
PTCH1 gene (15), and ovarian teratomas show increased 
methylation of the PTCH1 promoter (16). 
Ovarian dermoids are mature teratomas which often 
contain various differentiated tissues, for example glandular 
tissue, multilayered epithelium, hair follicles, bone, teeth and 
cartilage. Their development is attributed to aberrant meiosis 
of germinal cells within the ovary. Depending on the phase 
of meiosis during which the errors occur, the teratomas are 
roughly divided into 5 subtypes (17). Reports on the malign 
transformation of teratomas into carcinomas mostly describe 
squamous cell carcinoma, melanoma, adenocarcinoma, 
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neuroectodermal tumors, glioblastoma and sarcoma (18). Such 
events are rare; they occur in postmenopausal women in up to 
2% of all teratomas, and most frequently progress into squa-
mous cell carcinoma (19).
Our lab has been studying the mechanisms by which 
the Ptch protein takes part in the Hh-Gli signal transduc-
tion pathway and how aberrations in the pathway can lead 
to malignancy. Our previous findings showed the role of the 
PTCH1 gene in ovarian dermoids (20) and its association with 
Cyclin D (21), indicating the role of Hh-Gli signaling in the 
pathogenesis of this heterogenic neoplasia. 
Materials and methods
Immunohistochemical and immunofluorescent staining. 
Paraffin tissue slides were routinely prepared in the Department 
of Obstetrics and Gynecology, School of Medicine, Zagreb. 
For immunohistochemical staining, tissues were deparaf-
finized, endogenous peroxidase was blocked, the slides were 
heated in epitope-retrieval solution for 5 min at 85˚C to enable 
correct epitope folding, and stained using the following anti-
bodies diluted 1:100: goat polyclonal anti-Ptch (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA; sc-6147) (22), 
rabbit polyclonal anti-Smo (Santa Cruz; sc-19943) (23), rabbit 
polyclonal anti-Gli1 (Santa Cruz; sc-20687) (24) and rabbit 
polyclonal anti-Hh (Santa Cruz; sc-9024) (13). Secondary 
antibodies were bovine anti-goat-HRP and bovine anti-rabbit-
HRP, used at 1:100 dilution. For negative control, slides were 
treated in the same way omitting the primary antibody step. 
For positive control, parallel staining was performed on squa-
mous cell carcinoma slides which were positive for Ptch, Smo, 
Gli1 and Shh in our previous study (25).
For immunofluorescence, cells were seeded on glass 
coverslips and treated with 7.5 µM cyclopamine or 3 ng/µl Shh 
protein. After 24 h, cells were fixed using 3.5% paraformal-
dehyde solution, permeabilized with methanol, heated in 
epitope-retrieval solution for 5 min at 85˚C to enable correct 
epitope folding, and stained with the same primary antibodies 
used for immunohistochemistry, using the same dilutions. 
Secondary antibodies were conjugated with either Texas Red 
(TR) or Fluorescein (FITC), used at 1:100 dilution: donkey 
anti-goat-TR (Santa Cruz; sc-2783), mouse anti-goat-FITC 
(Santa Cruz; sc-2356), donkey anti-rabbit-TR (Santa Cruz, 
sc-2784), donkey anti-mouse-FITC (Santa Cruz; sc-2099) and 
nuclei were stained with DAPI. For negative control, slides 
were treated in the same way omitting the primary antibody 
step. 
Mutation detection. The PTCH1 gene was divided into 24 PCR 
products and analyzed using high-resolution melting analysis 
(26), followed by sequencing in both directions (27-29). For 
the SMO gene, only exons 9 and 10 were analyzed in the same 
manner (30).
Cell culture experiments. Dermoid tissue collected during 
surgery was stored for a maximum of 2-3 h in serum-free 
MEM culture medium at 4˚C. For primary culture, tissue was 
washed briefly in trypsin, and then cut into small fragments 
and digested in 5 ml trypsin overnight at 37˚C and 5% CO2. 
The following day the cells were resuspended and plated 
in several 10 cm petri dishes in MEM supplemented with 
20% human serum (HS). Dishes were regularly checked for cell 
colonies, which usually appeared after a week, approximately. 
Individual colonies were collected and grown separately, as 
separate clone lines.
Ten established primary clone lines and two ovarian 
cancer cell lines (COLO-704 and SkOv-3, a kind gift from 
Dr K. Rajalingam) were grown in MEM supplemented with 
10% HS or 0.5% HS. Cells were treated with 7.5 µM cyclo-
pamine (Toronto Research Chemicals), 7.5 µM tomatidine 
(Sigma-Aldrich, St. Louis, MO, USA), or 3 ng/µl Shh protein 
(a kind gift from Dr A. Kenney) for 24, 48 or 72 h. RNA was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA) and proteins were extracted by standard methods. MTT 
assay was performed as per the manufacturer's instructions. 
For western blot analysis, the primary antibodies for Ptch, 
Smo, Gli1 and Hh were the same ones that were used for immu-
nofluorescent staining, as well as goat anti-Actin (Santa Cruz; 
sc-1616). Secondary antibodies were bovine anti-goat-HRP 
and bovine anti-rabbit-HRP, and the signal was detected using 
SuperSignal West Pico (Pierce Biotechnology Inc., Rockford, 
IL, USA; #34077). 
Quantitative real-time PCR (qRT-PCR). One microgram of 
total RNA was reverse transcribed using TaqMan Reverse 
Transcription Reagents (Applied Biosystems). Quantitative 
real-time PCR was performed with the following primers: 
ARP F, 5'-GGCACCATTGAAATCCTGAGTGATGTG-3' 
and ARP R, 5'-TTGCGGACACCCTCCAGGAAGC-3'; PTCH 
F, 5'-TCCTCGTGTGCGCTGTCTTCCTTC-3' and PTCH R, 
5'-CGTCAGAAAGGCCAAAGCAACGTGA-3'; SMO F, 
5'-CTGGTACGAGGACGTGGAGG-3' and SMO R, 5'-AGG 
GTGAAGAGCGTGCAGAG-3'; GLI1 F, 5'-GCCGTGT 
AAAGCTCCAGTGAACACA-3' and GLI1 R, 5'-TCCCACT 
TTGAGAGGCCCATAGCAAG-3'; SHH F, 5'-GAAAGC 
AGAGAACTCGGTGG-3' and SHH R, 5'-GGTAAGT 
GAGGAAGTCGCTG-3' (25); SUFU F, 5'-AACAGCAA 
ACCTGTCCTTCC-3' and SUFU R, 5'-TCAGATGTACG 
CTCTCAAGC-3' (31); β-catenin F, 5'-GCGTGGACAA 
TGGCTACTCA-3' and β-catenin R, 5'-CCGCTTTTCT 
GTCTGGTTCC-3' (32). The reaction was performed in a 10 µl 
reaction using IQ SYBR-Green supermix (Bio-Rad), under the 
following conditions: initial denaturation at 95˚C for 3 min, 
and 40 cycles of 95˚C for 15 sec and 61˚C for 1 min. Melting 
curve of each product was examined after each real-time PCR 
experiment to verify their specificity, and expression was 
normalized using the ARP housekeeping gene. Relative gene 
expression was calculated using the 2-ΔΔCt formula, with RNA 
from the normal ovary used as the reference. Normal ovary 
sample was a pool of 9 RNA samples from healthy ovaries, 
taken during surgery at the Department of Obstetrics and 
Gynecology from patients operated for reasons other than 
malignant transformation. All patients gave their informed 
consent before the samples were obtained, and the samples 
were collected with the approval of the hospital's Ethics 
Committee (No 01-600/34-1-2007) in accordance with the 
Health Care Laws of the Republic of Croatia (NN121/03).
Confocal microscopy. Laser scanning confocal microscopy 
was performed on the Leica TCS SP2 AOBS instrument. 
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FITC emission was excited with the 488 nm laser and detected 
in the 499-576 nm range, whereas TR emission was excited 
with the 543 nm laser and detected in the 605-712 nm range. 
DAPI emission was excited with the 405 nm laser and detected 
in the 413-466 nm range. In order to prevent bleed-through 
of the FITC emission into the TR channel, images in the two 
channels were recorded sequentially. Cross-excitation of the 
FITC fluorophore by the green 543 nm laser was eliminated 
by adjusting the imaging conditions.
Results
Hh-Gli signaling pathway proteins can be detected in ovarian 
dermoids. Ovarian dermoids show a high level of differentia-
tion, with many structures typical for skin (epithelium, mucous 
glands, serous glands), and stromal and cortical regions of 
ovaries. Immunohistochemical staining of dermoid tissue 
sections revealed the presence of the main components of the 
Hh-Gli signaling pathway (Fig. 1). Ptch intensively stains the 
epithelium and many types of glandular tissue present in the 
sections, but not the connective tissue. It is mostly localized 
to the cell membrane, but in many cells it is also localized 
close to the nucleus (Fig. 1, insets). Smo is typically found in 
the same regions as Ptch. Staining of Gli1 is weak and mostly 
limited to the basal layer of the epithelium, but also within 
the oocyte in the follicles. Hh protein shows mostly epithelial 
staining, with the strongest intensity in the basal layer, but it is 
also localized to oocytes in the follicles and to zona pellucida 
in the secondary follicles. 
No PTCH1 or SMO mutations are detected in ovarian 
dermoids. To test whether the pathway activation is caused 
by inactivating mutations in the PTCH1 gene or activating 
mutations in the SMO gene, the entire coding region of 
PTCH1 including its promoter, and exons 9 and 10 of SMO 
were examined for mutations. No mutations were found in the 
SMO hot-spot region (exons 9 and 10). In the PTCH1 gene 
only three known polymorphisms were detected and all three 
were in heterozygous form. Polymorphisms were detected 
in exon 2 (c.318C>T), exon 12 (c.1665T>C) and intron 15 
(c.2560IVS+9G>C). The two exonic polymorphisms cause no 
change in the amino acid sequence, and all three polymor-
phisms are well documented (Patched Mutation Database 
www.cybergene.se/PTCH/).
Primary cultures derived from ovarian dermoids have a 
limited lifespan. Ten distinct clone lines were established 
from two dermoids, 5 lines from each sample. These cultures 
were established and maintained in MEM supplemented with 
10% human serum (HS) to match the conditions in vivo as 
closely as possible. Developed primary lines are vimentin-
positive, most likely mesenchymal in origin, with fibroblast 
morphology. Primary cultures had a limited lifespan and 
started to show morphology typical of ‘old’ cells at approxi-
mately the 10th passage (elongated shape, vacuolization, 
slowed division), and usually died out by the 15th passage. All 
experiments were performed at a passage number <10. 
Hh-Gli signaling pathway expression in ovarian dermoid 
primary cultures. mRNA expression was detected for PTCH1, 
SMO, GLI1, SUFU, and β-catenin in all ten clone lines. SHH 
expression was not detectable after 40 cycles of quantitative 
real-time PCR in 5/10 clone lines. Since the healthy ovarian 
tissue shows no expression of Hh-Gli pathway proteins when 
examined by immunohistochemistry (14), we examined the 
gene expression levels in the healthy ovary and compared 
them to gene expression levels in dermoid cultures. PTCH1 
and GLI1 expression, which are considered major markers of 
pathway activity, were upregulated in the dermoids compared 
to the normal ovary. PTCH1 levels were 40-100-fold higher 
in the dermoid than in the normal ovary, while GLI1 was not 
Figure 1. Immunohistochemical staining of the Ptch, Smo, Gli1 and Hh 
proteins in ovarian dermoid tissues, marked 1933 and DE505. Ptch and Smo 
are clearly stained on the cell membrane in the epithelium and glandular 
tissue, Gli1 shows a weak staining in the epithelium and oocytes, and the Hh 
staining pattern is very similar to Gli1. 
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detectable in the normal ovary, but was regularly detected 
in the dermoids with variations between the clone lines. 
β-catenin, which is regulated by the Hh-Gli signaling (33), 
was 25-40-fold more strongly expressed in the dermoid lines 
compared to the normal ovary (Fig. 2). Similar expression 
levels of the tested genes were also detected in the ovarian 
carcinoma cell lines SkOv-3 and COLO-704, which are also 
shown in Fig. 2.
Hh-Gli pathway proteins were also detected by western blot 
analysis. The Ptch protein was regularly detected in all clone 
lines. Smo and Gli1 expression was weaker than that of Ptch.
The Hh antibody we used shows reactivity to all three Hh 
proteins (Shh, Dhh, Ihh). In our experiments we detected one 
or two bands coresponding to approximately 50 kDa. Ovarian 
carcinoma cell lines showed a similar expression pattern of 
Hh-Gli pathway proteins. Cells grown in 0.5% HS, mimicking 
starvation, showed a far weaker signal for all pathway proteins, 
and Gli1 and Smo were often undetectable under these 
conditions (data not shown). Treatment with cyclopamine, 
tomatidine, or Shh protein did not change protein expression 
levels in any clone or cell line (Fig. 3). 
Primary cultures show reactivity to cyclopamine and Shh 
protein. Since all clone lines derived from two tumors showed 
expression of PTCH1, SMO, GLI1 and SUFU, one clone line 
from each tumor was used to determine the effect of the Smo 
inhibitor cyclopamine and responsiveness to Shh ligand. 
Cyclopamine-treated cells showed a significant delay in prolif-
eration as determined by MTT proliferation assay (Fig. 4). 
On the other hand, treatment with the Shh protein caused an 
increase in cell proliferation compared to non-treated cells. 
The ovarian carcinoma cell line shows responsiveness to 
cyclopamine inhibition, but is not stimulated by the exogenous 
addition of the ligand. To test whether cyclopamine treatment 
affects cell cycle, as suggested by Chen et al (14), we tested 
cell cycle distribution after treatment with cyclopamine or Shh 
protein. Neither treatment affects the cell cycle distribution of 
these cells, suggesting a different mechanism of action from 
cell cycle control (data not shown). 
Hh-Gli pathway proteins show altered localization after cyclo-
pamine or Shh treatment. Cyclopamine and Shh treatment 
modulate localization of Ptch and Gli1 proteins suggesting 
this as the major regulatory step in Hh-Gli signaling in the 
dermoids. Their localization was altered in all tested clone 
lines in the same way. Fig. 5 shows the effect of cyclopamine 
(CYC) or Shh ligand (SHH) treatment on Ptch, Smo and Gli1 
proteins compared to non-treated (NT) cells.
Figure 2. Relative expression of (A) PTCH1, (B) GLI1 and (C) β-catenin in 10 
ovarian dermoid clone lines (1933-2 to -6, and DE505-2 to -7) and two ovarian 
carcinoma cell lines (SkOv-3 and COLO704) compared to the normal ovary 
(NO). Relative fold change was calculated using the 2-ΔΔCt formula.
Figure 3. Western blot analysis of two different ovarian dermoid clone lines 
(one from each of the samples), as well as SkOv-3 ovarian cancer cell line, 
showing expression of Ptch, Smo, Gli1 and Hh proteins in non-treated cells, 
compared to cyclopamine, tomatidine or Shh protein-treated cells. No sig-
nificant changes in protein levels were detected after any of the treatments.
Figure 4. Cell proliferation was determined by MTT assay following treat-
ment with 7.5 µM cyclopamine or 3 ng/µl Shh protein for 72 h. Primary 
cultures and SkOv-3 cell line show a decrease in cell proliferation compared 
to non-treated cells, and primary cultures show an increase in proliferation 
after stimulation with the Shh protein.
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The Ptch protein was regularly detected diffused through 
the cytoplasm and in patches at the cell membrane (Fig. 5, 
columns 1 and 2). After cyclopamine treatment the staining 
was more diffuse, while Shh treatment induced accumula-
tion of dot-like structures in the cytoplasm. Smo protein was 
detected in the cytoplasm with a stronger staining of the cell 
membrane (Fig. 5, columns 3 and 4), and remained unchanged 
after either treatment. In non-treated cells the Gli1 protein 
was enriched in the nucleus compared to the cytoplasmic 
background. After treatment with cyclopamine, staining of 
the nucleus was decreased. Shh treatment had no significant 
effect on Gli1, since it was already localized in the nucleus and 
therefore active.
Treatment with the Shh protein had a remarkable effect on 
Ptch protein localization. After 24 h small bright dots of Ptch 
protein became visible in the cytoplasm, and after 48 h the 
dots increased in size and intensity. These cytoplasmatic Ptch 
aggregates were occasionally detected in untreated cells with 
lesser intensity (Fig. 6, NT), suggesting some baseline activity 
of the pathway, and were reduced in cyclopamine-treated cells 
(Fig. 6, CYC). When cells were stained with Ptch and Hh anti-
bodies, it was clear that the aggregates contained both Ptch and 
Hh protein, suggesting their joint internalization after binding 
(Fig. 6, white arrows). A basal level of pathway activity is visible 
in non-treated cells, is significantly increased in Shh-treated 
cells and is not detectable in cyclopamine-treated cells.
Previous studies suggest that Hh-Gli signaling in mammals 
requires the primary cilia to effectively transduce the signal 
(reviewed in ref. 34). Therefore cells were stained for acety-
lated tubulin to check for primary cilia formation and possible 
colocalization with the pathway proteins. Despite our efforts, 
we were unable to find a large number of ciliated cells regard-
less of growth conditions, but occasionally cilia-like structures 
were detected (data not shown).
Figure 5. Cells derived from both dermoid samples were treated with 7.5 µM cyclopamine or 3 ng/µl Shh protein, and protein localization was monitored with 
confocal microscopy. The Ptch protein is localized on the cell membrane and diffusely within the cell. Following Shh treatment it shows accumulation in the 
form of multiple dots in the cytoplasm. Following cyclopamine treatment, Ptch staining is diffused in the cytoplasm. The Smo protein is located on the cell 
membrane and in the cytoplasm, and its localization remains unchanged after either treatment. The Gli1 protein is located in the cytoplasm and more strongly 
in the nucleus, and after Shh treatment the signal is very similar to the unstimulated cells. Cyclopamine treatment reduces the intensity of Gli1 staining in the 
nucleus, which becomes less saturated than the surrounding cytoplasm. 
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Discussion
Involvement of Hh-Gli signaling in ovarian carcinogenesis 
has been demonstrated (14,15), but its detailed role in germ 
cell tumorigenesis has yet to be thoroughly examined. We 
used ovarian dermoids as they show characteristics of tumors 
and developmental malformations, and Hh-Gli signaling is 
involved in both processes. The structures which usually 
develop within dermoids belong to the tissue types that are 
controlled by Hh-Gli signaling in embryonic development, for 
example glandular tissue, hair follicles, bone, teeth and carti-
lage. Ovarian dermoids are classified as teratomas, a type of 
benign ovarian tumors, which contain differentiated elements 
derived from any of the three embryonic germ layers. The 
term ‘teratoma’ denotes the strange manifestations of benign 
or malignant tumors that possess the hallmarks of abnormal 
embryogenesis (35). 
Our results show different levels of gene expression of 
Hh-Gli pathway genes in different clones from the same 
tumor tissue sample, confirming the known observation of 
heterogeneity of dermoid tissues. Developed primary lines 
are vimentin-positive, most likely mesenchymal in origin, 
with fibroblast morphology. However, it is unclear whether 
this vimentin-positive, cytokeratine-negative phenotype is the 
marker of a mesenchymal cell, or a consequence of the Hh-Gli 
pathway activation, which can induce epithelial-mesenchymal 
transition (36,37). Also, ovarian cysts are one of the features of 
the Gorlin syndrome, which is caused by germline mutations 
in the PTCH1 gene. However, we did not detect any mutations 
in PTCH1 or SMO genes in the dermoid samples; only poly-
morphisms in exons 2 and 12 with no effect on amino acid 
sequence.
Results presented in this study demonstrate that the Hh-Gli 
signaling pathway is activated in the dermoid tissue, but not in 
the surrounding ovarian tissue. Major members of the pathway, 
namely Ptch, Smo, Gli1 and Hh, can be detected in the dermoid 
tissue, although Gli1 and Hh at lower levels than Ptch and Smo. 
This is not surprising since Gli1, as the transcription factor, 
plays a limiting role in controlling pathway activity. Hh-Gli 
signaling pathway genes PTCH1, SMO, GLI1 and SUFU are 
detected in all dermoid clone lines, with intensities similar to 
ovarian carcinoma cell lines. When dermoid primary cultures 
are compared to the normal ovary, PTCH1 and GLI1, major 
markers of pathway activity, are strongly upregulated, as well 
as β-catenin, one of the Hh-Gli signaling targets. Gli2 and 
Gli3 do not appear to be relevant in Hh-Gli pathway control 
in ovarian dermoids, since their gene and protein expression 
was extremely weak and often undetectable. SHH gene expres-
sion was detected in only five of the ten clone lines. When 
compared with western blot analysis, one to two Hh proteins 
Figure 6. Dermoid cells were treated with 7.5 µM cyclopamine or 3 ng/µl Shh protein, and Ptch and Hh protein colocalization was monitored with confocal 
microscopy. Hh protein is produced in ovarian dermoids and its staining is the strongest in the region surrounding the nucleus, most likely endoplasmatic 
reticulum. In the non-treated conditions (NT) a small number of Ptch cytoplasmatic dots is detected, suggesting a basal level of signaling activity. Upon 
Shh stimulation the number of these dots is dramatically increased and each of the dots also shows a signal for the Hh protein, suggesting their concomitant 
internalization. Cyclopamine-treated cells show only diffuse Ptch staining, while Hh production remains unaltered.
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are detected in ovarian dermoid primary cultures. Studies 
on mice have demonstrated that Dhh and Ihh are expressed 
in granulosa cells, pre-antral and antral follicles, and induce 
Hh-Gli signaling in the surrounding stroma (38). Therefore, 
the protein signal detected in our cells is more likely to be one 
of these two proteins.
Treatment with cyclopamine, a known inhibitor of the 
Hh-Gli pathway which binds to Smo and prevents downstream 
signaling, reduces cell proliferation in primary cultures and 
ovarian carcinoma cell line. On the other hand, Shh protein 
increases cell proliferation, and this effect has been previously 
demonstrated on mammalian neuronal precursors (39).
Protein localization demonstrated by confocal microscopy 
also corroborates previously published data: Gli1 is located in 
the cytoplasm and in the nucleus, whereas Ptch and Smo are 
located in the cytoplasm and on the cell membrane (10). Gli1 
changes localization after cyclopamine treatment, showing a 
reduction of the signal in the nuclear interior. 
It is well known that many membrane receptors are inter-
nalized and then degraded or recycled to the cell membrane 
(40). According to recent models, Ptch is also internalized 
upon Shh binding, allowing Smo to translocate to the cell 
membrane (41,42). Indeed, our results provide evidence for 
this internalization process. Addition of Shh protein induces 
the signal transduction, which leads to increased Ptch inter-
nalization, and colocalization of Ptch and Shh proteins within 
these granules in the cytoplasm (Fig. 5). 
It has been demonstrated that the primary cilia are required 
for Hh-Gli pathway regulation in mammalian development, 
where they act as a switch for turning the signaling on and off 
(34). However, the cilia are not required for the Drosophila 
Hh signaling, and the signaling events involving SuFu and 
Gli proteins are independent of cilia (43). Here, we detected 
structures that stain for acetylated tubulin, and resemble the 
primary cilia. However there was no enrichment of the Smo 
protein inside the cilia. Since the primary cilia are usually 
found on the surface of most growth-arrested and differentiated 
cells, it is not surprising that they were not detected more often 
in primary dermoid cells, since these were quite proliferative 
in culture. The role of primary cilia in tumorigenesis remains 
unclear, and published reports state that either the presence 
or the absence of cilia can enhance tumor growth, depending 
on the molecular context (44,45). It has been reported that 
Hh-Gli pathway responsiveness correlates with the presence 
of the primary cilia in prostate development (46). However, 
when prostate cancer cell lines were examined under different 
growth conditions, there was no evidence of cilia formation 
(46). The cilia were also normally detected in the ovary, more 
specifically in the granulosa cells of the pre-antral and antral 
follicles (47). When cultured, these cells exhibit cilia only after 
serum starvation and growth arrest, while normal interphase 
cells show a complex cytoskeletal network but no primary 
cilia (47). This, as well as our data, suggests that the pathway 
may be regulated differently in normal development compared 
to cancer, and further investigation of these differences may 
lead to potential Hh-Gli pathway-targeting drugs.
Teglund and Toftgard (1) proposed that Hedgehog-
associated tumors may have four different mechanisms of 
activation: the ligand-independent, the ligand-dependent 
autocrine, the ligand-dependent paracrine, and the ligand-
dependent reverse paracrine mechanism. The dermoids express 
Hh ligand, and show increased proliferation and changes in 
protein localization consistent with pathway activity. A basal 
level of pathway activity can be seen in all the clone lines and 
this is greatly increased by addition of the Shh ligand. Based 
on our observations, the mechanism of Hedgehog activation in 
the ovarian dermoids could be the ligand-dependent autocrine 
pathway, which can also be stimulated by paracrine signals. 
The basal level of autocrine activity may keep the cells in a 
‘ready’ state, prepared to react to outside stimulus, possibly 
by a signal from granulosa cells or developing follicles which 
are known to produce the Hh ligands. Since dermoids are 
considered to develop from aberrantly activated germinal cells 
within the ovary, their microenvironment which produces Hh 
ligands provides a proliferation signal and enables dermoid 
formation.
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